glp-1 news updates november 2025 Pipeline Update: - Prime Therapeutics GLP-1 | Summary

Real food you'll actually crave Real ingredients

Anti-Inflammatory Pathways Melanocortin receptor engagement on macrophages modulates NF-B signaling

Combined MEK and PARP inhibition enhances radiation response in rectal cancer

The primary aim of the present trial was to compare the effects of liraglutide 1.8 and 3.0 mg, the maximum approved dose in treatment of type 2 diabetes and the intended clinical dose in weight management, respectively, on gastric emptying in obese individuals without T2DM, with the focus on demonstrating equivalence between the two doses over a 5-h period, in order to support that no dose adjustment of concomitantly administered oral medications would be required during treatment with liraglutide 3.0 mg

Tsimberidou AM, Tirado-Gomez M, Andreeff M , O'Brien S, Kantarjian H, Keating M, Lopez-Berestein G, Estey E